Abstract
Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive axial muscle stiffness, central nervous system hyperexcitability, and painful stimulus-sensitive muscle spasms. A nationwide survey performed in 2018 showed the estimated prevalence of SPS was 0.2 per 100,000 population. Most patients with SPS had antibodies against glutamic acid decarboxylase 65, followed by antibodies to the glycine receptor α-subunit. Usually, patients with SPS showed favorable outcomes; however, some studies have reported intractable SPS. Early diagnosis and aggressive immunotherapy are necessary for management of patients with SPS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
